|20th August 2020||Bankole A. Johnson||350,000||Open or private sale||$1.21||$423,500.00|
|27th March 2020||James W. Jr. Newman||5,000||Open or private purchase||$1.42||$7,100.00|
|27th March 2020||James W. Jr. Newman||10,000||Open or private purchase||$1.34||$13,400.00|
|27th March 2020||James W. Jr. Newman||4,644||Open or private purchase||$1.35||$6,269.40|
|26th March 2020||William B. Iii Stilley||12,652||Open or private purchase||$1.47||$18,598.44|
|25th March 2020||William B. Iii Stilley||12,348||Open or private purchase||$1.13||$13,953.24|
|3rd March 2020||Joseph Truluck||27,084||Grant/award etc.||$0.00|
|3rd March 2020||William B. Iii Stilley||54,167||Grant/award etc.||$0.00|
|12th December 2019||Bankole A. Johnson||150,000||Open or private sale||$1.00||$150,000.00|
|2nd October 2019||Bankole A. Johnson||3,187||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial.